Literature DB >> 2154443

Efficacy of azithromycin for therapy of active syphilis in the rabbit model.

S A Lukehart1, M J Fohn, S A Baker-Zander.   

Abstract

Azithromycin was shown to be as effective as standard benzathine penicillin and erythromycin in the therapy of active syphilis in the rabbit model. Following production of primary chancres by intradermal inoculation of 10(6) Treponema pallidum, groups of six rabbits were treated with benzathine penicillin (200,000 units im weekly for two weeks), erythromycin base (30 mg/kg/day orally four times daily for 15 days) or azithromycin (30 mg/kg/day given orally once or twice daily for 15 days); one group was untreated. Daily darkfield (DF) microscopic examinations of chancre aspirates were conducted to identify motile organisms. Although all treated animals became DF negative prior to completion of therapy, the median time to DF negativity was longer in animals given azithromycin once daily, compared with animals receiving benzathine penicillin (P less than 0.01); no difference was seen in comparison with animals receiving erythromycin. Untreated animals remained DF positive for greater than 15 days. The mean maximum lesion diameters for all treated animals were similar and were significantly smaller than in untreated rabbits; fewer lesions ulcerated in treated than in untreated animals. Subsequent dose-ranging studies indicated that administration of lower doses of azithromycin (15 mg/kg/day given orally either once or twice daily, or 7.5 mg/kg/day given once daily) was as effective as benzathine penicillin for therapy of active syphilis in this model, though the median time to darkfield negativity was significantly longer in the azithromycin-treated animals (P less than 0.01). Persistent infection was demonstrable in lymph nodes of untreated animals, but no evidence of virulent T. pallidum was found three months following transfer of tissue from any animal treated with penicillin, erythromycin, or azithromycin.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2154443     DOI: 10.1093/jac/25.suppl_a.91

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  13 in total

Review 1.  Syphilis: review with emphasis on clinical, epidemiologic, and some biologic features.

Authors:  A E Singh; B Romanowski
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

Review 2.  The activity of azithromycin in animal models of infection.

Authors:  J C Pechère
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

3.  Detection of azithromycin resistance in Treponema pallidum by real-time PCR.

Authors:  Mark W Pandori; Charmie Gordones; Lina Castro; Joseph Engelman; Mark Siedner; Sheila Lukehart; Jeffrey Klausner
Journal:  Antimicrob Agents Chemother       Date:  2007-07-09       Impact factor: 5.191

4.  Azithromycin and syphilis.

Authors:  F J Bowden; B Farmer; J Bullen; V Chamberlain; I Bastian
Journal:  Genitourin Med       Date:  1995-06

Review 5.  Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy.

Authors:  D H Peters; H A Friedel; D McTavish
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

Review 6.  Rabbit Models for Studying Human Infectious Diseases.

Authors:  Xuwen Peng; John A Knouse; Krista M Hernon
Journal:  Comp Med       Date:  2015-12       Impact factor: 0.982

Review 7.  Syphilis in the HIV-infected patient: an update on epidemiology, diagnosis, and management.

Authors:  Jonathan Zellan; Michael Augenbraun
Journal:  Curr HIV/AIDS Rep       Date:  2004-09       Impact factor: 5.495

8.  The Diagnosis and Management of Syphilis in the HIV-Infected Patient.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-02       Impact factor: 3.663

9.  The 1998 CDC Sexually Transmitted Diseases Treatment Guidelines.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-02       Impact factor: 3.663

10.  Jarisch-Herxheimer reaction among HIV-positive patients with early syphilis: azithromycin versus benzathine penicillin G therapy.

Authors:  Mao-Song Tsai; Chia-Jui Yang; Nan-Yao Lee; Szu-Min Hsieh; Yu-Hui Lin; Hsin-Yun Sun; Wang-Huei Sheng; Kuan-Yeh Lee; Shan-Ping Yang; Wen-Chun Liu; Pei-Ying Wu; Wen-Chien Ko; Chien-Ching Hung
Journal:  J Int AIDS Soc       Date:  2014-08-28       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.